BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 37016182)

  • 1. Drug target therapy and emerging clinical relevance of exosomes in meningeal tumors.
    Sharma S; Rana R; Prakash P; Ganguly NK
    Mol Cell Biochem; 2024 Jan; 479(1):127-170. PubMed ID: 37016182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Update Knowledge for Brain Tumors(7)Meningioma].
    Kawahara N
    No Shinkei Geka; 2016 May; 44(5):415-30. PubMed ID: 27166847
    [No Abstract]   [Full Text] [Related]  

  • 3. Exosome-based Tumor Therapy: Opportunities and Challenges.
    Li C; Hou X; Zhang P; Li J; Liu X; Wang Y; Guan Q; Zhou Y
    Curr Drug Metab; 2020; 21(5):339-351. PubMed ID: 32410558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of chemotherapy and targeted therapy in the treatment of intracranial meningioma.
    Chamberlain MC
    Curr Opin Oncol; 2012 Nov; 24(6):666-71. PubMed ID: 22759739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toll-like receptor-4 is expressed in meningiomas and mediates the antiproliferative action of paclitaxel.
    Tichomirowa MA; Theodoropoulou M; Daly AF; Yassouridis A; Hansen S; Lu J; Lange M; Goldbrunner RH; Stalla GK; Renner U
    Int J Cancer; 2008 Oct; 123(8):1956-63. PubMed ID: 18688857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design.
    Everson RG; Hashimoto Y; Freeman JL; Hodges TR; Huse J; Zhou S; Xiu J; Spetzler D; Sanai N; Kim L; Kesari S; Brenner A; De Monte F; Heimberger A; Raza SM
    J Neurooncol; 2018 Sep; 139(2):469-478. PubMed ID: 29846894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive overview of extracellular vesicle proteomics in meningioma: future strategy.
    Rana R; Sharma S; Ganguly NK
    Mol Biol Rep; 2021 Dec; 48(12):8061-8074. PubMed ID: 34687392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosome-based nanoimmunotherapy targeting TAMs, a promising strategy for glioma.
    Luo H; Zhang H; Mao J; Cao H; Tao Y; Zhao G; Zhang Z; Zhang N; Liu Z; Zhang J; Luo P; Xia Y; Cheng Y; Xie Z; Cheng Q; Liu G
    Cell Death Dis; 2023 Apr; 14(4):235. PubMed ID: 37012233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells.
    Al-Khalaf HH; Lach B; Allam A; Hassounah M; Alkhani A; Elkum N; Alrokayan SA; Aboussekhra A
    Brain Res; 2008 Jan; 1188():25-34. PubMed ID: 18048012
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
    Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
    Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. M2-Macrophage-Derived Exosomes Promote Meningioma Progression through TGF-
    Fu XH; Li JP; Li XY; Tan Y; Zhao M; Zhang SF; Wu XD; Xu JG
    J Immunol Res; 2022; 2022():8326591. PubMed ID: 35637794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent anaplastic meningioma treated by sunitinib based on results from quantitative proteomics.
    Yoshikawa A; Nakada M; Ohtsuki S; Hayashi Y; Obuchi W; Sato Y; Ikeda C; Watanabe T; Kawahara Y; Hasegawa T; Sabit H; Kita D; Hayashi Y; Nakanuma Y; Terasaki T; Hamada JI
    Neuropathol Appl Neurobiol; 2012 Feb; 38(1):105-10. PubMed ID: 21696419
    [No Abstract]   [Full Text] [Related]  

  • 13. Chemotherapy: What is its role in meningioma?
    Sherman WJ; Raizer JJ
    Expert Rev Neurother; 2012 Oct; 12(10):1189-95; quiz 1196. PubMed ID: 23082735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosomes: Cell-Derived Nanoplatforms for the Delivery of Cancer Therapeutics.
    Kim H; Kim EH; Kwak G; Chi SG; Kim SH; Yang Y
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33374978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
    Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
    Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted drug therapy for meningiomas.
    Norden AD; Drappatz J; Wen PY
    Neurosurg Focus; 2007; 23(4):E12. PubMed ID: 17961036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel therapies for meningiomas.
    Wen PY; Drappatz J
    Expert Rev Neurother; 2006 Oct; 6(10):1447-64. PubMed ID: 17078786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. mTOR Signaling and Potential Therapeutic Targeting in Meningioma.
    Pinker B; Barciszewska AM
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments in chemotherapy for meningiomas: a review.
    Moazzam AA; Wagle N; Zada G
    Neurosurg Focus; 2013 Dec; 35(6):E18. PubMed ID: 24289126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mebendazole and radiation in combination increase survival through anticancer mechanisms in an intracranial rodent model of malignant meningioma.
    Skibinski CG; Williamson T; Riggins GJ
    J Neurooncol; 2018 Dec; 140(3):529-538. PubMed ID: 30414098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.